Product Description
Mechanisms of Action: THR-B Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Adrenoleukodystrophy
Phase 1: Adreno-myeloneuropathy|Adrenoleukodystrophy|Cognition Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CCALD | P2 |
Withdrawn |
Adrenoleukodystrophy |
2020-12-01 |
29% |
| 2017-001684-21 | P1 |
Terminated |
Adrenoleukodystrophy |
2019-12-09 |
|
| Sobetirome-CLIN-006 | P1 |
Withdrawn |
Adreno-myeloneuropathy|Adrenoleukodystrophy |
2013-09-01 |
|
| Brain Uptake of GSK1034702 | P1 |
Completed |
Cognition Disorders |
2009-08-28 |